Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?

At a general hospital level, Hellgren et al., retrospectively analyzing data from 83 patients with RRMS, PPMS, and SPMS, reported a highly significant reduction of ARR induced by rituximab (500 or 1,000 mg every 6–12 months) from mean 0.38 ± 0.5 before treatment initiation to mean 0.05 ± 0.19 at follow-up (p<0.00001), with a global reduction by 87% ( 82 ).

also in 132,142 other papers

Compared with fingolimod and natalizumab, ARR and GAD+ lesions were numerically lower but did not reach statistical significance.

also in 111,027 other papers